NCT01928576: A reported trial by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01928576 |
|---|---|
| Title | A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer. |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Nov. 6, 2013 |
| Completion date | April 4, 2023 |
| Required reporting date | April 3, 2024, midnight |
| Actual reporting date | Feb. 1, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |